Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.

Autor: Aldardeer NF; Critical Care Clinical Pharmacy Consultant, Medical and Clinical Affairs Department, King Faisal Specialist Hospital and Research Center, P.O. Box 40047, Jeddah, 21499, Saudi Arabia. aldardeern@hotmail.com., Labban HM; Pediatric Antimicrobial Stewardship Clinical Pharmacist , King Saud Medical City, Riyadh, Saudi Arabia., Alhuthil RT; Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Aljahdali SH; Pharmacist, Saudi German Hospital , Makkah, Saudi Arabia., Alharbi MH; Saudi German Hospital, Makkah, Saudi Arabia., Alharbi RA; Pharmacy Department, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia., Al Musawa MI; Anti-Infective Research Laboratory, Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA., Almalki AA; Clinical Pharmacist, Medical and Critical Care Pharmacy, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia., Almangour TA; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: BMC infectious diseases [BMC Infect Dis] 2024 Dec 22; Vol. 24 (1), pp. 1455. Date of Electronic Publication: 2024 Dec 22.
DOI: 10.1186/s12879-024-10365-5
Abstrakt: Background: The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents. Thus, this study aims to assess the effectiveness of traditional NCBL compared to novel β-lactam agents (NVL) for treating non-carbapenem β-lactam -susceptible CRPA.
Methods: A single-center retrospective cohort study was conducted between January 2016 and December 2022. The study included adult patients 18 years and older with infection due to CRPA who were treated based on microbiology sensitivity with traditional NCBL or NVL for more than 48 h. The primary outcome was 30-day mortality.
Results: 124 patients were included: 98 (79%) in the NCBL group and 26 (20.9%) in the NVL group. 78 (62.9%) patients were male. The median (interquartile range (IQR)) age of included patients was 64 (45, 77) years. A total of 84 (67.7%) patients were critically ill, with an overall median (IQR) APACHE II score of 18 (13.5, 23). The rates of 30-day mortality in NCBL and NVL groups were 41 (41.8%) and 12 (46.2%), respectively; P = 0.692.
Conclusion: In patients with CRPA infections susceptible to traditional NCBL, there was no statisticallly significant difference in 30-day mortality among patients who were treated with traditional NCBL compared with NVL. Further studies with larger sample sizes are needed to confirm these findings.
Competing Interests: Declarations. Ethics approval and consent to participate: The study was approved by the institutional review board of KFSHRC-J (IRB#2023-81). The data were kept confidential; no one except the research team had access to the files. As the data were collected retrospectively, the institutional review board of KFSHRC-J waived the consent to participate as per the rules and regulations of the Kingdom regarding the conduct of research and the IRB and international policies on human subject protection and confidentiality rights. This study was implemented following Good Clinical Research Practice (Declaration of Helsinki) and the rules and guidelines of the Ethics Committee in KFSHRC. Consent for publication: Not applicable. Clinical trial number: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje